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Overline: GENETIC DIAGNOSIS 
One Sentence Summary: 
AMELIE parses primary literature about Mendelian diseases to rank patient candidate causative 




The diagnosis of Mendelian disorders requires labor-intensive literature research. Trained 
clinicians can spend hours looking for the right publication(s) supporting a single gene that best 
explains a patient’s disease. AMELIE (Automatic Mendelian Literature Evaluation) greatly 
accelerates this process. AMELIE parses all 29 million PubMed abstracts, and downloads and 
further parses hundreds of thousands of full text articles in search of information supporting the 
causality and associated phenotypes of most published genetic variants. AMELIE then prioritizes 
patient candidate variants for their likelihood of explaining any patient’s given set of phenotypes. 
Diagnosis of singleton patients (without relatives’ exomes) is the most time-consuming scenario, 
and AMELIE ranked the causative gene at the very top for 66% of 215 diagnosed singleton 
Mendelian patients from the Deciphering Developmental Disorders project. Evaluating only the 
top 11 AMELIE scored genes of 127 (median) candidate genes per patient resulted in a rapid 
diagnosis in 90+% of cases. AMELIE-based evaluation of all cases was 3-19x more efficient 
than hand-curated database-based approaches. We replicated these results on a retrospective 
cohort of clinical cases from Stanford Children’s Health and the Manton Center for Orphan 
Disease Research. An analysis web portal with our most recent update, programmatic interface 





Millions of babies born worldwide each year are affected by severe genetic, often Mendelian 
disorders (1). Patients with Mendelian diseases have one or two genetic variants in a single gene 
primarily responsible for their disease phenotypes (2). Roughly 5,000 Mendelian diseases, each 
with a characteristic set of phenotypes, have been mapped to about 3,500 genes to date (3). 
Exome sequencing is often performed to identify candidate causative genes, resulting in a 
relatively high (currently 30%) diagnostic yield (4). A genetic diagnosis provides a sense of 
closure to the patient family, aids in patient trajectory prediction and management, allows for 
better family counseling, and in the age of gene editing even provides first hope for a cure. 
However, identifying the causative mutation(s) in a patient’s exome to arrive at a diagnosis can 
be very time-consuming, with a typical exome requiring hours of expert analysis (5).  
Definitive diagnosis of a known Mendelian disorder is accomplished by matching the 
patient’s genotype and phenotype to previously described cases from the literature. Manually 
curated databases (6–10) are utilized to more efficiently access extracts of the unstructured 
knowledge in the primary literature. Automatic gene ranking tools (11–18) use these databases to 
prioritize candidate genes in patients’ genomes for their ability to explain patient phenotypes. An 
important feature of many gene ranking tools is the use of phenotype match functions on patient 
phenotypes and gene- or disease-associated phenotypes. Phenotype match functions exploit the 
structure of a phenotype ontology (9) and known gene-disease-phenotype associations to 
quantify the inexact match between two sets of phenotypes (11, 12), with recent approaches 
developed to computationally extract phenotype data from electronic medical notes (19, 20). The 
goal of all gene ranking tools is to aid a busy clinician in arriving at a definitive diagnosis of any 
case presented to them in the shortest amount of time, by reading up on genes in the order the 
algorithm has ranked them. 
Given the rapidly growing number of rare diseases with a known molecular basis (21) and the 
difficulty of manually finding a diagnosis for some rare diseases with variable phenotypes, many 
patients experience long diagnostic odysseys (22). Expert clinician time is expensive and scarce, 
but machine time is cheap and plentiful. We aimed to accelerate the diagnosis of patients with 
Mendelian diseases by using information from primary literature to construct gene rankings, thus 
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allowing clinicians to discover the causative gene along with supporting literature in a minimum 
amount of time. 
Here, we introduce AMELIE (Automatic Mendelian Literature Evaluation). AMELIE uses 
natural language processing (NLP) to automatically construct a homogeneous knowledgebase 
about Mendelian diseases directly from primary literature. To perform this operation, AMELIE 
was trained on data from manually curated databases such as Online Mendelian Inheritance in 
Man (OMIM) (6), Human Gene Mutation Database (HGMD) (8) and ClinVar (10). AMELIE 
then used a machine learning classifier that integrated knowledge about a patient’s phenotype 
and genotype with its knowledgebase to rank candidate genes in the patient’s genome for their 
likelihood of being causative, and simultaneously supported its ranking results with annotated 
citations to the primary literature. We compare this end-to-end machine learning approach to 
gene ranking methods that rely on manually curated databases using a total of 271 singleton 
patients from 3 different sources, including 2 clinical centers and a research cohort. 
Results 
Overview of AMELIE 
Given a patient’s genome sequencing data and a phenotypic description of the patient, 
AMELIE aims to both identify the gene causing the patient’s disease (when possible) and supply 
the clinician with literature supporting the gene’s causal role. To this end, AMELIE creates a 
ranking of candidate causative genes in the patient’s genome with the aim of ranking the true 
causative gene at the top. AMELIE constructs its candidate causative gene ranking by comparing 
information from the primary literature to information about the patient’s genotype and 
phenotype. 
To process information from the full text of primary literature, AMELIE constructs a 
knowledgebase directly from the primary literature up-front using natural language processing 
techniques trained on manually curated databases. After knowledgebase construction, AMELIE 
ranks any patient’s candidate causative genes using a classifier, which compares knowledge from 
the AMELIE knowledgebase with phenotypic and genotypic information about the patient. 




Identification and download of relevant Mendelian disease articles based on all of PubMed 
The first step towards building the AMELIE knowledgebase was discovering relevant primary 
literature. Of 29 million peer-reviewed articles deposited in PubMed, only a fraction is relevant 
for Mendelian disease diagnosis. We constructed a machine learning classifier that, given titles 
and abstracts of articles from PubMed, identified potentially relevant articles for the AMELIE 
knowledgebase. 
Machine learning classifiers take as input a numerical vector describing the input, called the 
“feature vector”. Here, we used a so-called TF-IDF transformation to convert input text into a 
feature vector. We implemented the title/abstract document classifier as a logistic regression 
classifier. Logistic regression transforms its output using the logistic sigmoid function to return a 
probability value which is then mapped into binary (positive/negative) decision making (23). 
Machine learning classifiers learn to classify an input as positive (relevant) or negative 
(irrelevant) by being exposed to a large number of labeled positive and negative examples (the 
training set). OMIM (6) is an online database of Mendelian diseases, genes, and associated 
phenotypes. HGMD (8) is a database of disease-causing mutations in the human genome. The 
training set for the title/abstract relevance classifier consisted of titles and abstracts of 56,479 
Mendelian-disease-related articles cited in OMIM and HGMD as positive training examples, and 
67,774 random titles and abstracts of PubMed articles (largely unrelated to Mendelian disease) as 
negative training examples. 
Precision and recall are two standard measures of evaluating classifier performance. Precision 
measures the fraction of all inputs classified positive that are truly relevant. Recall measures the 
fraction of truly positive inputs that are classified positive. Five-fold cross-validation (splitting 
all available labeled training data to include 80% in a training set and evaluating on the 
remaining 20%, 5 times in round-robin fashion) returned an average precision of 98% and an 
average recall of 96%.  
All 28,925,544 titles and abstracts available in PubMed on September 30, 2018, were 
downloaded and processed by the document classifier. The classifier identified 578,944 articles 
as possibly relevant based on their PubMed title and abstract, of which we downloaded 515,659 
(89%) full text articles directly from dozens of different publishers.  
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Building a structured database of information about Mendelian diseases from full text 
From the full text of an article, multiple types of information were extracted. Gene mentions 
in full text were identified using lists of gene and protein names and synonyms from the HUGO 
Gene Nomenclature Committee (HGNC) (24), UniProt (25) and the automatically curated 
PubTator (26), an NCBI service combining gene mentions discovered by multiple previously 
published automatic gene recognition methods. AMELIE recognized approximately 93% of 
disease-causing gene names. However, through a combination of unfortunate gene synonyms 
(such as “FOR”, “TYPE”, “ANOVA”, or “CO2”), as well as genes mentioned only in titles of 
cited references, or interaction partners of causative genes, a median of 12 distinct gene 
candidates were discovered in each article (table S1). 
To discover which gene(s) were the subject of the PubMed article, each distinct gene 
candidate extracted from an article received a “relevant gene score” between 0 and 1 indicating 
the likelihood of the gene being important in the context of the article. Training data for the 
relevant gene classifier was obtained from OMIM and HGMD. A total of 304,471 downloaded 
full-text articles contained at least one gene with a relevance score of 0.1 or higher. These 
articles, along with their above-threshold scoring genes, formed the AMELIE knowledgebase. 
Articles in the AMELIE knowledgebase contained a median of 1 gene with a relevant gene score 
between 0.1 and 1 (table S1). Further, genetic variants (for example, “p.Met88Ile” or 
“c.251A>G”) were identified in the full text of each article and converted to genomic coordinates 
(chromosome, position, reference and alternative allele) using the AVADA variant extraction 
method (27). A median of 3 distinct genetic variants were extracted from 123,073 full-text 
articles in the AMELIE knowledgebase. 
Phenotype mentions were recognized in full text articles using a list of phenotype names 
compiled from Human Phenotype Ontology (HPO) (9). By linking all genes with a relevant gene 
score of at least 0.5 in an article with all phenotypes mentioned in the same article, we arrived at 
a total of 872,080 gene-phenotype relationships covering 11,537 genes (fig. S1).  
Five scores between 0 and 1 were assigned to the full text of each article. A “full-text 
document relevance” score assessed the likely relevance of the article for the diagnosis of 
Mendelian diseases. A “protein-truncating” and a “non-truncating” score each gave an 
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assessment of whether the article was about a disease caused by protein-truncating (splice-site, 
frameshift, stopgain) or non-truncating (other) variants. A “dominant” and a “recessive” score 
each gave an assessment of the discussed inheritance mode(s) in the article.  
Precision and recall of full-text article information (relevant genes, extracted phenotypes, full-
text article scores) varied between 74% and 96%. All the data described in this section were 
entered into the AMELIE knowledgebase, keyed on the article they were extracted from (Fig. 
1A). The top journals from which the most gene-phenotype relationships were extracted are 
shown in Fig. 1B and table S2. We estimated that the number of newly described gene-
phenotype relationships has increased by an average of 10.5% every two years since the year 
2000 (fig. S2). 
The AMELIE classifier assigns patient genes a likelihood of being causative 
Given a patient with a suspected Mendelian disease, AMELIE aims to speed up discovery of 
the causative gene by ranking patient genes for their ability to describe a patient set of 
phenotypes. AMELIE performs standard filtering of the patient variant list (21, 28) to keep only 
“candidate causative variants” that are rare in the unaffected population and are predicted to 
change a protein-coding region (missense, frameshift, nonframeshift indel, core splice-site, 
stoploss, and stopgain variants). Core splice sites were defined to consist of the 2 basepairs at 
either end of each intron. Genes containing candidate causative variants were called candidate 
causative genes (or “candidate genes”). AMELIE ranked approximately 97% of known disease-
causing mutations, excluding only those in deeper intronic and non-protein-coding intergenic 
regions. 
We defined an article in the AMELIE knowledgebase to be about a candidate causative gene 
if the candidate causative gene had a relevant gene score of at least 0.1 in the article to maximize 
recall while maintaining a median of 1 relevant gene per article. We constructed a machine 
learning classifier called the “AMELIE classifier” that assigns a score between 0 and 100 to 
triples (P, G, A) consisting of a set of patient phenotypes P, a candidate causative gene G, and an 
article A about the candidate gene. Given a patient with phenotypes P and a candidate gene G, 
the AMELIE score indicates whether the article A is likely helpful for diagnosing the patient 
because it links mutations in G to the patient’s phenotypes P. Higher AMELIE scores indicate 
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articles more likely relevant to diagnosis. The AMELIE classifier was implemented as a logistic 
regression classifier and returns a score between 0 and 100 called the “AMELIE score”. The 
AMELIE score is used to both rank patient candidate genes and explain rankings by citing 
primary literature, as described below. 
The AMELIE classifier uses a set of 27 real-valued features, falling into 6 feature groups (Fig. 
1C). The 6 feature groups comprise: (1) 5 features containing information about disease 
inheritance mode extracted from the article and patient variant zygosity. (2) 5 features containing 
information about AVADA-extracted variants from the article and overlap of these variants with 
patient variants. (3) 2 features containing information about patient phenotypes based on the 
Phrank (11) phenotypic match score of phenotypes in article A with the patient phenotypes P. (4) 
5 features containing information about article and patient variant types. (5) 3 features containing 
information about article relevance and relevance of the candidate gene in the article, and (6) 7 
features containing a priori information about the patient’s candidate causative variants in G such 
as in-silico pathogenicity scores (29) and gene-level mutation intolerance scores (30, 31). 
To train the AMELIE classifier, we constructed a set of 681 simulated patients using data 
from OMIM (6), ClinVar (10), and the 1000 Genomes Project (32). Each simulated patient s was 
assigned a disease from OMIM, with phenotypes noisily sampled from the phenotypes 
associated with the disease. The genome of each simulated patient was based on genome 
sequencing data from the 1000 Genomes Project. An appropriate disease-causing variant from 
ClinVar was added to each simulated patient’s genome. Each simulated patient was assigned a 
diagnostic article As describing the genetic cause of the patient’s disease. In total, the simulated 
patients covered a total of 681 OMIM diseases (1 per patient) and a total of 1,090 distinct 
phenotypic abnormalities (table S3). The sampled phenotypes for each disease covered an 
average 21% of the phenotypes manually associated with the disease by HPO. 
The AMELIE classifier was trained to recognize the diagnostic article As out of all articles 
about genes with candidate causative variants in a patient s. Of a total of 681 training “patients” 
constructed using data in OMIM and ClinVar, the single positively labeled article was 
recognized and downloaded during AMELIE knowledgebase construction in 664 cases (98%), 
creating 664 positive training examples. The negative training set for the AMELIE classifier 
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consisted of triples (Ps, G, A) for each simulated patient s where G was a non-causative candidate 
gene in patient s, and A was an article about G. For training efficiency, we used only 664,000 
random negative training examples out of all available negative training examples. 
The AMELIE classifier assigns each candidate gene G an AMELIE score, defined as the best 
AMELIE classifier score for any paper A about gene G, as it relates to patient P (Fig. 1C). 
Candidate causative genes were ranked in descending order of their associated score. 
Evaluating AMELIE on a retrospective patient test set 
We evaluated AMELIE on a set of 215 real singleton patients with an established diagnosis 
from the Deciphering Developmental Disorders (DDD) project (33). The DDD dataset included 
HPO phenotypes (a median of 7 per patient), exome data in variant call format (VCF), and the 
causative gene for each patient (1 per patient). AMELIE’s goal was to rank the established 
causative gene at or near the top of its ranked list of candidate genes for each patient. Filtering 
for candidate causative variants resulted in a median of 163 variants in 127 candidate genes per 
patient Fig. 1C). We used the set of 215 patients obtained from the DDD study to evaluate 
AMELIE against Exomiser (14), Phenolyzer (15), Phen-Gen (16), eXtasy (17), and 
PubCaseFinder (18). The output of all methods, consisting of a list of ranked genes, was subset 
to the (median) 127 candidate genes that AMELIE used for each patient based on the filtering 
criteria previously described (Fig. 2A). This ensured the fair evaluation of all gene ranking 
methods against the same set of genes. 
AMELIE analyzed a median of 4,173 articles per patient and ranked the causative gene at the 
very top in 142 (66%) out of 215 cases, and in the top 10 in 193 cases (89.7%). Other methods 
ranked the causative gene at the top between 38% of cases (Exomiser) and 8% of cases (Phen-
Gen) (Fig. 2B). AMELIE performed significantly better than all compared methods (all p-values 
≤ 1.68*10-9; one-sided Wilcoxon signed rank test; table S4). Of 117 distinct top-ranked articles 
supporting the DDD patients where AMELIE ranked the test set causative gene at number 1, 
only 36 (31%) were cited in OMIM as determined by a systematic Google search of omim.org 
(table S5). 
Due to the large number of patients expected to be sequenced for Mendelian diagnosis (34), 
one may want to set guidelines for rapid vs. in-depth exome or genome analysis. In our test set of 
10 
 
215 patients, AMELIE offered a diagnosis for 90% of diagnosable cases when evaluating only 
up to the top 11 AMELIE-ranked genes per case, or 9% of a median of 127 candidate causative 
genes. If using any of the other methods, the clinician would have to investigate between a 
median of 30 genes (when using Exomiser to rank patient candidate causative genes) and 108 
genes per patient to arrive at the diagnosis in 90% of diagnosable cases (Fig. 2C). 
If the clinician used AMELIE to determine the order in which they evaluate their entire 
candidate gene list, one gene after the other, on the DDD set of 215 patients, they would evaluate 
a total of 735 gene-patient matches to arrive at the causative gene for all 215 patients. If the 
clinician went through the list of candidate genes in random order, they would evaluate an 
expected total sum of 14,383 gene-patient matches to arrive at the causative gene for all patients. 
By this metric, AMELIE improved diagnosis time by a factor of 19.6x over a random baseline. 
The next best tool, Exomiser, would require the clinician to read about 2,085 genes until arriving 
at the causative gene for all patients, an improvement of 6.9x faster over a random baseline. The 
performance of other methods ranged from a speedup of 3.13x to 1.04x (Fig. 2D). The speedup 
provided by AMELIE was thus more than twice that provided by the next-best tool, Exomiser. 
Replication of AMELIE performance on 56 clinical cases from two sites 
To test for result replication across data sources, we evaluated AMELIE using 56 singleton 
clinical cases seen by the Medical Genetics Service at Stanford Children’s Health and the 
Manton Center for Orphan Disease Research at Boston Children’s Hospital. Patient genotype 
and phenotype data were obtained from Stanford and the Manton Center Gene Discovery Core.  
We performed a comparison of gene ranking performance using AMELIE against other methods 
as above for the DDD patients. AMELIE ranked the causative gene at the very top in 33 (59%) 
out of 56 cases, and in the top 10 in 50 cases (89%). Again, AMELIE significantly outperformed 
all other methods (all p-values ≤ 6.65*10-3; one-sided Wilcoxon signed rank test; fig. S3A and 
table S6). AMELIE offered a diagnosis for 90% of patients in the test set of 56 Stanford and 
Manton patients if evaluating the top 15 candidate genes per patient (9% of a median of 172.5), 
replicating its performance on the DDD set (fig. S3B).  
To arrive at the causative gene for each patient in the clinical test set from Stanford and 
Manton when using AMELIE, a clinician would need to evaluate 300 genes, compared to a 
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baseline of 6,106 genes if evaluating genes in random order. Similar to the DDD patient test set, 
AMELIE resulted in a speedup of 20x compared to the baseline, 2-20x faster than  other methods 
(fig. S3C). Since the other methods do not use simulated patients for training, gene ranking 
results using other methods were obtained by running each respective method once on the 
simulated patients set. 5-fold cross-validation on the 681 simulated patients showed that 
AMELIE generated significantly better causative gene rankings compared to the other methods 
(all p-values ≤ 5.24*10-10; fig. S4, and table S7).  
We ran multiple tests with modified AMELIE knowledgebases and AMELIE classifiers to 
dissect the relative contribution of different AMELIE components to its causative gene ranking 
performance. For all 175 test cohort patients with the causative gene ranked at the top, we 
investigated which machine learning features of the AMELIE classifier contributed most to the 
high score of the causative gene. Overwhelmingly, for 149 (85%) of 175 real test patients, the 
feature contributing most to the high score was a high phenotypic match between the patient and 
the article. However, 14 out of a total 27 AMELIE classifier features (52%) occurred at least 
once within the 3 features contributing most to the top rank of a patient’s causative gene (Fig. 3A 
and table S8). 
To measure how much AMELIE relied on certain feature groups, we re-trained the AMELIE 
classifier 6 times, each time dropping one of its 6 feature groups. With dropped-out features, the 
number of causative genes ranked at the top across the test set of 271 real patients shrank 
between 4% and 39% (Fig. 3B and table S9). AMELIE did not better rank causative genes when 
phenotype recognition was augmented by data from UMLS (35), MeSH (36), and SNOMED-CT 
(37), three databases containing additional phenotype names and synonyms. However, AMELIE 
ranked 32% more causative genes at the top when using full-text data rather than data gathered 
only from titles and abstracts. 
 
AMELIE’s performance is not correlated with number of articles about a causative gene 
We investigated whether the number of articles about the causative gene in the AMELIE 
knowledgebase correlated with the causative gene rank by performing linear regression between 
the causative gene rank and number of articles analyzed for the causative gene. The regression 
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revealed no significant relationship (p=0.85 that the slope of regression equals 0 according to a 
Wald Test with t-distribution of the test statistic; Fig. 3C), suggesting that AMELIE performs 
well independent of the number of papers it has analyzed about a causative gene. For the 22 
patients (8% of a total of 271 real test patients) with less than 10 papers analyzed for the 
causative gene, AMELIE ranked causative genes at the top for 10 (45%) cases. In contrast, 
Exomiser ranked the causative gene at the top in 6 (27%) of these cases.  
The AMELIE knowledgebase and AMELIE classifier work together to arrive at high 
causative gene ranks 
We investigated the relative contribution of the AMELIE classifier and the AMELIE 
knowledgebase to AMELIE’s overall gene ranking performance. We re-trained the AMELIE 
classifier using data from DisGeNET (38), a text mining-based database containing gene-
phenotype relationships, disease-causing variants, and links to primary literature from PubMed. 
Using DisGeNET data resulted in significantly worse causative gene rankings compared to the 
AMELIE knowledgebase (p ≤ 4.76*10-23; table S10). We then replaced the AMELIE classifier 
(Fig. 1C) with the Phrank (11) phenotypic match score to estimate the impact of the AMELIE 
classifier on overall AMELIE performance. Gene ranking by the Phrank phenotypic match score 
resulted in ranking 94 (35%) of 271 real patients’ causative genes at the top, significantly worse 
compared to the AMELIE classifier, which ranked 175 causative genes at the top (p=1.33*10-11, 
one-sided Wilcoxon signed rank test). We conclude that the AMELIE knowledgebase and the 
AMELIE classifier work together to achieve AMELIE’s high causative gene-ranking 
performance. 
Interactive and programmatic access to AMELIE-based literature analysis 
AMELIE can be used through its web portal at https://AMELIE.stanford.edu to utilize 
AMELIE for patient analysis. The portal offers both an interactive interface (fig. S5) and an 
application programming interface (API) that enables integrating AMELIE into any computer-
assisted clinical workflow. The AMELIE knowledgebase will be updated every year. A pilot of 
AMELIE has been running at this web address since August 2017, as a service to the 
community, using an AMELIE knowledgebase automatically curated from articles published 




We present AMELIE, a method for ranking candidate causative genes and supporting articles 
from the primary literature in patients with suspected Mendelian disorders. We show that 
AMELIE ranks the causative gene first (among a median of 127 genes) in 2 out of 3 of patients, 
and within the top 11 genes in over 90% of 215 real patient cases. These results were closely 
replicated on a cohort of 56 clinical patients from Stanford Children’s Health and the Manton 
Center for Orphan Disease Research.  
Mendelian disease diagnosis is a complex problem and clinicians or researchers can spend 
many hours evaluating a single case. With 5,000 diagnosable Mendelian diseases caused by 
roughly 3,500 different genes that manifest in different subsets of over 13,000 documented 
phenotypes, manual patient diagnosis from the primary literature is highly labor intensive. 
Manually curated databases like OMIM, OrphaNet, and HGMD take a step towards alleviating 
clinician burden by attempting to summarize the current literature. However, manual curation is 
growing ever more challenging as the literature about Mendelian diseases is increasing at an 
accelerating rate. Based on AMELIE analysis, the number of gene-phenotype relationships in 
Mendelian literature has been increasing by an average of 10.5% every two years since the year 
2000. Because AMELIE is an automatic curation approach requiring only an initial critical mass 
of human curated data to train on, it is not constrained by the bottleneck of on-going human 
curation. For example, of 117 top-ranked articles supporting the DDD patients where AMELIE 
ranked the test set causative gene at number 1, only 36 (31%) were cited in OMIM. OMIM, a 
manually curated database, does not, of course, promise to capture all papers pertaining to any 
given disease gene, but an automated effort like AMELIE can.  
Compared to existing gene-ranking approaches, AMELIE replaces the notion of a fixed 
disease description (that is, a single set of phenotypes) with the notion of an article and the 
phenotypes described in it. This approach has multiple advantages. First, it is often fastest to 
convince a clinician about a diagnosis given an article directly describing the disease, which 
often includes disease information such as patient images and related literature. Additionally, 
with considerable phenotypic variability in Mendelian diseases (39), matching patients to 
specific reports in the literature is conceptually more helpful for definitive diagnosis than 
14 
 
matching to a disease, which is effectively a compendium of previously described patient 
phenotypes.  
Due to its dependence on literature and exome sequencing data, AMELIE is subject to a 
number of limitations. Biomedical literature is not guaranteed to contain the full set of 
phenotypes known to be associated with a disease, and AMELIE makes no claim about capturing 
this full set. Rather, AMELIE focuses on causal gene ranking using its knowledgebase, and as 
we show, it already does it to great practical utility. Certain articles about Mendelian diseases 
may mention a very small number of phenotypes (or none at all) and just mention disease and 
causative genes. Although this situation does not appear to be very common in practice (as seen 
by the good performance of AMELIE), the problem could be alleviated by automatically parsing 
disease names from such articles and associating diseases with manually curated phenotype 
information from resources such as HPO. Natural language processing approaches could also be 
used to read additional texts as well, such as electronic medical notes (19, 20). Further, AMELIE 
requires as input a list of HPO terms to describe patient phenotypes, although these may be 
provided by tools such as ClinPhen (19) that automatically extract HPO phenotypes directly 
from free-text clinical notes. Last, AMELIE is hampered by access to literature. Although 
AMELIE successfully obtained 80% of full-text articles that it deemed relevant based on title 
and abstract, better publisher programmatic access to full-text literature for the purposes of text 
mining may lead to even better gene ranking results. 
Understanding the impact of hundreds of thousands of variants in thousands of different genes 
against a body of knowledge of millions of peer reviewed papers that is ever expanding is a 
challenging task. Because a diagnosis shapes the future management of a patient, there must 
always be a human expert approving every diagnosis. But the sheer number of patients that can 
benefit from a molecular diagnosis and our intention to sequence millions of them in the next 
few years absolutely necessitate automating as much as possible of the diagnostic process, to 
potentiate rapid, affordable, reproducible and accessible clinical genome-wide diagnosis. As 
such, along with complementary medical record parsing tools (19, 20), AMELIE provides an 




Materials and Methods 
Study design 
We implemented a natural language processing and machine learning system dubbed 
“AMELIE” (for Automatic Mendelian Literature Evaluation) to automatically identify candidate 
causative genes in patients with Mendelian (monogenic) diseases based on information in 
primary literature. The system consists of two components: a knowledgebase constructed directly 
from primary literature, and a classifier that ranks candidate causative genes for a patient with a 
Mendelian disease.  
To construct the AMELIE knowledgebase, we trained logistic regression classifiers (23) 
largely on OMIM (6) and HGMD (8) data to identify potentially relevant PubMed abstracts. 
Similar classifiers were used to determine full text relevance and identify disease-causing genes, 
phenotypes, disease inheritance modes, disease-causing variants, and disease-causing variant 
types from abstract and article text.  
The AMELIE classifier was implemented as a logistic regression classifier (23). We 
constructed a set of 681 simulated patients with a single disease-causing variant using data from 
the 1000 Genomes Project (32), OMIM (6), Human Phenotype Ontology (HPO) (9), and 
ClinVar. The AMELIE classifier was trained to recognize the simulated patients’ disease-causing 
genes (positive training examples) against a background of non-disease-causing genes (negative 
training examples). 
We evaluated AMELIE against other knowledgebases and gene ranking tools using a set of 
215 previously diagnosed patients from the Deciphering Developmental Disorders (DDD) 
project (33). The DDD study has UK Research Ethics Committee approval (10/H0305/83, 
granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland 
REC). Each patient was associated with a candidate gene list generated using variant frequency 
filtering techniques, notably by restricting variant frequency to <= 0.5% minor allele frequency 
in a large control cohort (30). Using the DDD patient data, we compared AMELIE against 5 
other gene ranking tools (Exomiser (14), Phenolyzer (15), Phen-Gen (16), eXtasy (17), and 
PubCaseFinder (18). We replicated the results on the DDD cohort by combining 35 patients from 
Stanford Children’s Health and 21 patients from the Manton Center for Orphan Disease 
16 
 
Research into a further set of 56 test patients. Informed consent was obtained from all 
participants. Further details about the AMELIE algorithm are provided in the Supplementary 
Materials and Methods. 
Statistical analysis 
To test performance differences between any two different gene ranking methods, we used the 
one-sided Wilcoxon signed-rank test throughout the manuscript. P< 0.05 was considered 
significant. No adjustments to alpha level or multiple testing correction methods were applied. 
The Wilcoxon signed rank test is a nonparametric test and does not assume any particular 
distribution of the data. We used this test to compare two matched samples: in our case, two lists 
of causative gene ranks on the same set of patients generated by two different methods. To test 
for significance of the slope of the regression line in Fig. 3C, we used the Wald Test with t-
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Figure 1. AMELIE knowledgebase creation and subsequent patient causal gene ranking 
classifier.  
(A) AMELIE knowledgebase creation. AMELIE applies multiple machine learning classifiers to 
all (current) 29 million PubMed abstracts to parse, predict relevance, download full text, and 
finally extract Mendelian gene-phenotype relationships and related attributes automatically. (B) 
Number of gene-phenotype relationships extracted from the 10 journals that AMELIE extracted 
most gene-phenotype relationships from. (C) The AMELIE classifier combines 27 features to 
rank all articles in the AMELIE knowledgebase for their ability to explain any input patient. 
Figure 2. AMELIE patient causative gene ranking outperforms methods based on manually 
curated databases.  
(A) Evaluation scheme. The output gene ranking of all algorithms was subset to the same list of 
candidate genes AMELIE uses for its gene ranking to ensure a fair comparison. (B) Fraction of 
(n=215) DDD cases ranked as 1, 1-2 or 1-3 by six different tools. (C) The number of top-ranked 
genes needed to achieve a 90% diagnosis rate across (n=215) DDD cases by various gene 
ranking tools. By evaluating up to AMELIE’s 11th top-ranked gene, a 90% diagnosis yield on the 
DDD cases was achieved. The next best tool, Exomiser, achieved a 90% diagnosis yield by 
evaluating up to Exomiser’s 30th gene. (D) The speedup in terms of number of genes to 
investigate when perusing the ranked gene lists provided by each tool from top to bottom until 
the causative gene was found, compared to the expected value of a random baseline gene 
ordering for (n=215) DDD cases.  
Figure 3. Investigating AMELIE’s gene ranking performance. 
(A) For each of the 175 patients with AMELIE causative gene rank 1 among all (n=271) real 
DDD, Stanford, and Manton patients, the 27 features to the AMELIE classifier were ranked by 
their contribution to the top-ranked article’s high score. The panels, left-to-right, show the 
fraction of patients for which certain features were ranked most-, 2nd most-, or 3rd most- 
contributing.  PTV: protein-truncating variant; NTV: Non-protein-truncating variant, MCAP: 
Mendelian clinically applicable pathogenicity score, an in-silico pathogenicity score; PV: patient 
variant; het: heterozygous; EV: full text article-extracted variant. (B) Re-training the AMELIE 
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classifier with 5-fold cross-validation, each time omitting one of AMELIE’s 6 feature groups, 
shows the degree to which feature groups aided performance across all (n=271) DDD, Stanford 
and Manton patients. (C) Each blue dot represents one of (n=271) real DDD, Stanford, or 
Manton patients in this log-log plot. The red line is a linear regression line between number of 
articles about causative gene (x-axis) and causative gene rank (y-axis), with red denoting the 




Supplementary Materials  
Materials and Methods 
Parsing all of PubMed to construct a knowledgebase about Mendelian diseases 
Downloading titles and abstracts from PubMed 
PubMed is an online database that contains titles and abstracts of peer-reviewed biomedical 
articles. We downloaded titles and abstracts directly from PubMed 
(ftp://ftp.ncbi.nlm.nih.gov/pubmed/baseline/ and ftp://ftp.ncbi.nlm.nih.gov/pubmed/updatefiles/).   
Identifying phenotype mentions in titles and abstracts 
Human Phenotype Ontology (9) (HPO) provides a standardized vocabulary of phenotypic 
abnormalities encountered in human genetic disease. Phenotypic abnormalities are stored in HPO 
with a unique identifier, a canonical name and an optional list of synonyms. To identify 
phenotype mentions in English text, an AMELIE database of 45,435 phenotype phrases (names 
and synonyms of phenotypes and simplified versions thereof) corresponding to 13,439 HPO 
phenotypic abnormalities was created using phenotype names and synonyms from the HPO 
ontology version releases/2018-07-25, which we use throughout this manuscript. HPO names 
and synonyms are stored in the database in both exact and lemmatized forms. Lemmatization is 
an algorithmic process that reduces inflection forms of words to a common base form of the 
word. For example, the word “ovaries” is reduced to the singular form “ovary” after 
lemmatization. Lemmatized versions of words are created by the Python 3.7.0 NLTK version 
3.2.5 WordNetLemmatizer. Stopwords are short words such as “or”, “of”, “a”, “the”, etc. 126 
common stopwords were removed from all lemmatized phenotype names in the AMELIE 
database of phenotype names.  
Before any further processing for both phenotype and gene identification (described below), 
all text is passed through a filter replacing Greek letters and non-alphanumeric characters with 
canonical symbols, and sentence and word tokenization using Python 3.7.0 NLTK version 3.2.5. 
Sentence and word tokenization splits a single stream of text into individual sentences and 
words. To extract phenotypes from English text, all permutations of consecutive word groups of 
length 1 to 8 are systematically matched against the AMELIE database of phenotype names in 
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both lemmatized forms (after removal of stopwords) and exact forms. If a word group matches, it 
is associated with the appropriate HPO identifier. 
Identifying gene mentions in titles and abstracts 
Genes and their protein products are identified by various names in English text. Both the 
HUGO Gene Nomenclature Committee (HGNC) (24) and the UniProt (25) database maintain a 
list of gene and protein names. To identify mentions of human genes or their protein products in 
text, an AMELIE database of gene names, consisting of 188,975 gene and protein names for 
21,346 distinct protein-coding Ensembl version 84 genes and 18,149 non-protein-coding genes 
(which are largely used as negative training examples for the classifiers described below) was 
compiled from HGNC and UniProt. Data for mapping Ensembl genes to HGNC and UniProt was 
downloaded from BioMart (http://uswest.ensembl.org/biomart/) on October 28, 2016. AMELIE 
identifies gene mentions in articles by matching words groups in the article against the AMELIE 
database of gene names. Mentions of both gene names and names of their protein products are 
treated equally, and referred to as “gene mentions”. Further, PubTator (26) is an online tool that 
uses an ensemble of automatic text processing tools to identify gene mentions in PubMed titles 
and abstracts. Gene mentions identified by PubTator are used to supplement gene identification 
using the list of gene and protein names described above.  
To identify gene mentions in English text, all word groups of length 1-8 in the text are 
examined. Given an article identified by a PubMed ID, the database of gene and protein names is 
supplemented by the gene and protein names stored in PubTator for this PubMed ID. To identify 
gene mentions, word groups from the article are matched against the AMELIE database of gene 
names (case-insensitive). If a word group matches an entry in the AMELIE gene names database, 
it is associated with the matching Ensembl ID(s) and corresponding HGNC gene name(s) stored 
in the database of gene and protein names. 
Constructing a title/abstract document classifier 
PubMed contains titles and abstracts, but not the full text of articles. AMELIE uses a 
document classifier to discover articles that may be relevant to Mendelian diseases using the text 
in the article’s title and abstract, as well as gene and phenotype names discovered in the title and 
abstract. It then downloads the full text of potentially relevant articles.  
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To classify titles and abstracts as potentially relevant, gene and phenotype mentions were 
identified in the text as described above. Subsequently, all gene mentions were replaced by the 
token “XGENE” and all phenotype mention were replaced by the token “XPHENO” except for 
phenotypes descending from the following subtrees of HPO: neoplasm, prostate cancer, 
schizophrenia, abnormality of DNA repair (HP:0002664, HP:0012125, HP:0100753, 
HP:0003254, respectively). These phenotypes are often not transmitted in a Mendelian fashion, 
and occur in a large body of literature that is not of interest for Mendelian diagnosis. All words 
in the title were prefixed with “TITLE_” and all words in the abstract were prefixed with 
“ABSTRACT_”.  
To transform a document into a feature vector, we used the so-called TF-IDF transformation. 
A TF-IDF transformation treats each document as an unordered bag of words. The document is 
transformed into a feature vector by assigning each word the scalar product of two statistics: the 
term frequency (TF) of the word and the inverse document frequency (IDF) of the word. The 
term frequency tf(w, d) of a word w in a document d is defined to be the number of occurrences 
of w in d. The inverse document frequency of a word w in a document d is defined as 




where nd is the total number of documents and df(w) is the number of documents that contain 
the word w. (See also http://scikit-learn.org/stable/modules/feature_extraction.html - text-feature-
extraction). Then 
𝑡𝑓𝑖𝑑𝑓(𝑤, 𝑑) = 𝑡𝑓(𝑤, 𝑑) × 𝑖𝑑𝑓(𝑤, 𝑑). 
Here and below, to transform text data to a TF-IDF vector, we used a scikit-learn (41) version 
0.20.0 TfidfVectorizer with default parameters.  
To construct a training set for the title/abstract document classifier, we used data from OMIM 
gene entries and entries in HGMD. A “gene entry” in OMIM is an OMIM entry containing 
information on a particular gene, such as https://omim.org/entry/602635 (the OMIM entry for the 
gene DEAF1). “Allelic Variants” sections are sections in gene entries in the database OMIM 
(such as https://omim.org/entry/602635#allelicVariants). “Allelic Variants” sections in OMIM 
gene entries, amongst others, cite literature describing pathogenic mutations in the respective 
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gene. HGMD is a database of pathogenic and disease-associated variants in the human genome 
that is curated from the literature. We used HGMD PRO version 2018.01. Allelic variants entries 
from OMIM were downloaded on September 29, 2018. Entries in HGMD reference PubMed IDs 
of articles from which the pathogenic variants were curated. The training set for the title/abstract 
document classifier was based on all articles cited in OMIM’s “Allelic Variants” sections and in 
HGMD as positives, and random negative articles from PubMed. Titles and abstracts in the 
training set were TF-IDF transformed, labeled with 1 (“relevant”) or 0 (“irrelevant”) and used to 
train a scikit-learn (41) version 0.20.0 LogisticRegression classifier with a maximum of 1000 
iterations and default parameters otherwise.  
The document classifier was subsequently applied to TF-IDF-transformed titles and abstracts 
downloaded from PubMed. The classifier returns values between 0 and 1. Here and 
subsequently, classifiers are evaluated at cutoff value 0.5 to determine precision and recall (with 
samples with a classifier score >0.5 being classified as positives and samples with a classifier 
score <= 0.5 being classified as negatives).  
Regularization of title/abstract document classifier 
“Regularization” in machine learning refers to a process in which the machine learning 
classifier is penalized for learning complicated parameters that may fit the training data better 
than real-world data. For training logistic regression classifiers, two regularization schemes 
named “L2 regularization” and “L1 regularization” are commonly used. We chose the default L2 
regularization for all classifiers, including the title/abstract document classifier, as L1 
regularization of the title/abstract document classifier led to a slight drop in precision. 
Downloading full text of relevant articles 
Relevant documents identified using the title/abstract document classifier were downloaded 
using the pubCrawl2 software from the PubMunch3 version 1.0.3 package (42). Given a PubMed 
ID, the PubMunch software attempts to retrieve the full text PDF of a scientific article directly 
from its publisher. Downloaded articles in PDF format were converted to text using pdftotext 
version 0.26.5 (https://poppler.freedesktop.org/). 
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Identifying genes and phenotypes in relevant articles’ full text 
Genes and phenotypes were identified in full text in the same way they were identified in 
titles and abstracts (see above). PubTator-identified gene names from titles and abstracts were 
also used to identify gene mentions in full text.  
Determining sensitivity of gene name recognition in full text articles 
To quantify the sensitivity of gene recognition using HGNC and UniProt, we selected all 
39,431 articles cited in HGMD entries on disease-causing mutations that were classified as 
relevant by the title/abstract classifier for which we had downloaded the full text. Each HGMD 
entry contains the gene in which the disease-causing mutation occurs. Gene recognition with 
HGNC and UniProt alone recognized the name of the gene cited in HGMD in 89% of all articles. 
Augmenting the list of gene names using gene names deposited in PubTator, which relies on 
multiple previously published specialized gene recognition tools, increased sensitivity to 93%. In 
recent years, publishers have increasingly pushed to used HGNC gene names in publications; 
consequently, sensitivity of gene name recognition with UniProt and HGNC gene names alone 
increases to 92% in articles published since 2013, and to 94% if gene name lists were augmented 
with PubTator-extracted gene names (as done by AMELIE). 
Constructing a relevant gene classifier 
Many gene names recognized by AMELIE in an article are either false positives (e.g., 
“ANOVA”) or not relevant for diagnosis of Mendelian diseases (e.g., a gene mentioned in 
passing). To identify the most relevant (disease-causing) gene(s) in each article, a “relevant 
gene” classifier was trained to recognize genes that are mentioned in an article as causing a 
phenotype when mutated. For example, the gene NOTCH3 is the “relevant gene” of the article 
“Truncating mutations in the last exon of NOTCH3 cause lateral meningocele syndrome” 
(PubMed ID 25394726) and thus has a high relevant gene score in this article. We use articles 
cited in OMIM “Allelic Variants” sections and HGMD to construct a training set for the 
“relevant gene” classifier.  
Articles cited in OMIM “Allelic Variants” sections were associated with the corresponding 
OMIM gene in whose entry they were cited. For example, the article “Mutations affecting the 
SAND domain of DEAF1 cause intellectual disability with severe speech impairment and 
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behavioral problems”, which was cited in the “Allelic Variants” sections of the OMIM entry on 
DEAF1 (https://omim.org/entry/602635), was associated with DEAF1 as its “relevant gene” in 
the positive training set. This process was repeated across all OMIM “Allelic Variants” sections 
to construct the positive training set. To further enlarge the positive training set, we used articles 
associated with variants cited in HGMD. Articles A with relevant genes G were added to the 
positive training set if there was a variant in HGMD associated with gene G and article A. 
Articles associated with more than 3 relevant genes were omitted from the positive training set. 
The negative training set consisted of all article-gene mappings where the article is in the 
positive training set, and the gene is mentioned in the article, but the article-gene mapping is not 
part of the positive training set. This resulted in 47,357 positive training examples and 919,255 
negative training examples. 
Given a tuple consisting of an article A and a gene G, the following features were constructed 
for the relevant gene classifier: number of mentions of the gene G in the title of the article A, 
number of mentions of the gene G in the abstract of the article A, number of mentions of the gene 
G in the full text of the article A, and TF-IDF-transformed word counts (defined above) in 5-
word-windows around all mentions of the gene G in the full text of the article A.  
A scikit-learn (41) 0.20.0 LogisticRegression classifier with default parameters was 
subsequently trained using this training set. The classifier was applied to all gene objects in all 
downloaded articles.  
Full-text document classification assigns an article relevance based on the article’s full text 
Even if the title and abstract of an article seem potentially relevant enough to download the 
article, the full text of an article may turn out not to be relevant for AMELIE. We trained a full-
text classifier that assigns a likelihood of the article describing a link between genetic mutations 
and a Mendelian disease based on the article’s full text. 
The training set for the full-text document classifier consisted of a large number of (positive) 
full-text articles that are relevant, and a large number of (negative) full-text articles that are 
presumably irrelevant. To create the negative training set, random PubMed IDs were selected 
from all available PubMed IDs that were not part of the positive training set of the title/abstract 
document classifier and downloaded using PubMunch. 54,023 positive examples were obtained 
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using OMIM and HGMD and 159,665 random negative examples were obtained from all of 
PubMed. To convert each article’s full text into a feature vector, recognized gene and phenotype 
names were replaced by tokens “XGENE” and “XPHENO” in the full text of each article. A 
scikit-learn (41) 0.20.0 LogisticRegression classifier with default parameters was subsequently 
trained on TF-IDF transformed documents to serve as the full-text document classifier. This full-
text document classifier was applied to all downloaded articles. 
Variant type classifier identifies mentions of loss-of-function and gain-of-function variants in 
articles 
Two large classes of variants cause most known Mendelian diseases: variants that completely 
disrupt the wild-type transcript or translation into a chain of amino acids downstream of the 
mutation (including frameshift, stopgain and splicing mutations), and, variants that merely 
change a small portion of the resulting protein (including nonsynonymous and nonframeshift 
indel mutations). We call the former class “protein-truncating variants” (PTV) and the latter 
“non-truncating variants” (NTV). 
“Allelic Variants” sections in OMIM gene entries list disease-causing genetic mutations and 
give a textual synopsis of original literature describing the mutation, including a reference to the 
original article. We used OMIM “Allelic Variants” sections to create a training set for the variant 
type classifier. To this end, the “Allelic Variants” sections of all available OMIM entries on 
genes were parsed to construct a training set consisting of article-to-variant-type mappings. 
“Allelic Variants” sections that described more than one causative mutation or were longer than 
one paragraph were discarded for simplicity. Parts of sentences delimited by commas and 
periods in “Allelic Variants” sections that contained the words “originally described” or 
“originally reported” were ignored because articles referenced in such sentences most often 
describe patient phenotypes without describing causative mutations.  
To identify the variant type described in an “Allelic Variants” section, the mutation given in 
the “Allelic Variants” section was parsed using regular expression patterns covering missense, 
stoploss, splicing, deletion, duplication, and insertion variants (table S11). For all mutations 
fitting a pattern, from the paragraph describing the mutation, all mentioned PubMed IDs were 
extracted. If a single PubMed ID was extracted, it was labeled as either about NTVs (missense 
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variants, deletion and duplication variants of length 3, 6, or 9) or PTVs (stopgain, stoploss, 
splicing, and all remaining deletion and duplication variants). This resulted in a training set of 
5,131 articles about protein-truncating variants and 11,389 articles about non-truncating variants 
using data obtained from OMIM. Further, all available 3,178 PubMed IDs from the GWAS 
catalog v1.0 studies, release 2018-04-10 were added to the training set and labeled as neither 
about PTVs nor NTVs. A scikit-learn (41) 0.20.0 multi-class LogisticRegression classifier with 
default parameters were subsequently trained on TF-IDF transformed documents using the 
labeled article set. The trained classifier was applied to all downloaded, TF-IDF transformed 
articles.  
Inheritance mode classifier identifies articles about dominant and recessive diseases 
Mendelian diseases are inherited in a number of inheritance modes, notably autosomal 
dominant and recessive, and X-linked dominant and recessive. For simplicity, AMELIE uses 
only the notion of “dominant” and “recessive” to distinguish inheritance modes. For the purposes 
of AMELIE, a dominant disease can manifest itself if only one copy of the causative gene is 
mutated. A recessive disease manifests itself if all copies of the causative gene are mutated. 
The training set for the inheritance mode classifiers consisted of a large number of article-to-
inheritance-mode mappings. To create such a training set, the “Allelic Variants” sections of all 
available OMIM entries on genes were parsed. Allelic Variants sections were downloaded from 
OMIM on September 29, 2018. Each paragraph describing a mutation was first parsed sentence 
by sentence to detect keywords indicating a particular inheritance mode. Sentence tokenization 
was performed by Python 3.7.0 NLTK version 3.2.5. If a sentence contained any of the words 
“parent”, “brother”, “sister”, “sibling”, “family”, “mother”, or “father”, the sentence was 
omitted. Sentences were subsequently split into words by whitespace. If any sentence in the 
paragraph contained the words “homozygous”, “homozygote”, “homozygosity”, “recessive”, or 
“compound het”, the paragraph was marked as “recessive”. If any sentence in the paragraph 
contained the words “heterozygous”, “heterozygote”, “heterozygosity”, but not “compound 
heterozygous”, the paragraph was marked as “dominant”. Unmarked paragraphs or paragraphs 
marked as both “dominant” and “recessive” were omitted from all further analysis.  
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Subsequently, PubMed IDs of articles were parsed from each paragraph in the “Allelic 
Variants” sections. If a paragraph mentioned a single article, the article was associated with the 
inheritance mode extracted from the paragraph. This resulted in a training set of 6,157 
“recessive” articles and 4,276 “dominant” articles using data obtained from OMIM. Similar to 
the variant type classifier, all available 3,178 PubMed IDs from the GWAS catalog v1.0 studies, 
release 2018-04-10, were added to the training set as being neither about dominant nor recessive 
diseases. A scikit-learn (41) 0.20.0 multi-class LogisticRegression classifier with default 
parameters were subsequently trained on TF-IDF transformed documents and applied to all 
downloaded articles.  
Determining precision and recall of information extracted from full text 
To estimate the precision of the phenotype identifier on full text, 50 automatically identified 
phenotype mentions were randomly selected from all downloaded full-text articles and the 
number of correctly identified phenotypes was counted, resulting in a precision of 74% (table 
S12). A mention was defined as correct if the word group occurred referred to a phenotype and 
the associated HPO ID referred to the mentioned phenotype. 
5-fold cross-validation was performed using the Python 3.7.0 scikit-learn 0.20.0 function 
sklearn.model_selection.cross_validate. 5-fold cross-validation of the relevant gene classifier 
resulted in an average precision of 87% and an average recall of 76%. 5-fold cross-validation of 
the full-text document relevance classifier returned an average precision of 96% and an average 
recall of 91%. 
For 5-fold cross-validation of the protein-truncating/non-truncating classifier and the 
dominant/recessive classifier, precision and recall were computed using micro-averaging, in 
which all outcomes (here, “PTV”, “NTV”, or “neither”) have an equal contribution to the final 
precision and recall scores. 5-fold cross-validation of the protein-truncating/non-truncating 
variant type classifier returned an average precision and recall of 79% each. Similarly, 5-fold 




Variant identification in full text 
We used AVADA (27) to extract variant mentions from full text and convert them to genomic 
coordinates. 
Gene-phenotype statistics 
When reporting number of genes and number of gene-phenotype statistics in the AMELIE 
knowledgebase, we counted HGNC gene symbols and relationships between HGNC gene 
symbols and HPO phenotypes in the AMELIE knowledgebase except where otherwise noted. 
Training a classifier to assign genes a likelihood of being causative 
Variant filtering to arrive at candidate causative variants and genes 
ANNOVAR (43) (Version: $Date: 2017-06-01 23:07:59 -0400 (Thu,  1 Jun 2017) $) was 
used to annotate patient variants with predicted effect and frequency information. ANNOVAR 
supporting data for genome assembly GRCh37/hg19 was downloaded from the ANNOVAR 
website on August 28, 2017 using the command “./annovar/annotate_variation.pl -downdb” for 
ANNOVAR databases refGene, knownGene, and ensGene. Patient variants are annotated with 
frequency information from ExAC version 0.3 (30) and the 1000 Genomes Project (KGP) phase 
3 data (32), as previously described (21). A variant was considered rare if the allele frequency 
was less than 0.5% in the ExAC and KGP control databases and if it occurred in at most 1 
homozygous person in ExAC and KGP. Single heterozygous variants were only considered rare 
if the allele frequency was at most 0.1% in ExAC and KGP and if the allele count was at most 3. 
Rare missense, core splice-site (defined as the 2 basepairs at either end of each intron), 
frameshift, nonframeshift indel, stop-gain and stop-loss variants in Ensembl protein-coding 
genes were considered to be candidate causative variants. Genes containing candidate causative 
variants are considered candidate causative genes (or “candidate genes” for short). 
Estimating the fraction of known disease-causing mutations that AMELIE can rank 
To estimate the fraction of clinically relevant variants that AMELIE can rank using this 
variant filtering scheme, we annotated all 164,618 disease-causing (“DM”) variants available in 
HGMD version 2018.01 with predicted effect on genomic regions using the ANNOVAR 
predicted variant effects column “Gene.gene”. Of these, 146,423 (89%) fell into exonic regions 
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of protein-coding genes, and 12,590 (8%) fell into core splice-site regions of protein-coding 
genes. Only 4,469 (2.7%) of disease-causing variants fell into deeper intronic regions and 1,136 
(0.69%) fell into other genomic regions. Thus, AMELIE retains approximately 97% of known 
disease-causing variants. 
Discovery of articles about each of the candidate causative genes 
Given a patient’s list of candidate genes, for each candidate gene G, AMELIE analyzes all 
articles A if the relevant gene score of G in A is at least 0.1.  
AMELIE classifier feature set construction 
Each patient is associated with a set of phenotypes P, a list of candidate causative genes G, and a 
list of all AMELIE knowledgebase articles A about each candidate gene G. Each triple (P, G, A) 
was transformed into a feature vector that enabled the AMELIE classifier to calculate a 
likelihood that the article A explains the patient’s phenotypes P in light of the patient’s 
mutation(s) in G. Each such triple (P, G, A) is associated with a set of 27 real-valued features 
that enable the AMELIE classifier to calculate a likelihood that the article A explains how the 
patient’s variants in G cause the patient’s phenotypes P (Figure 1c). Two of these features use 
the Phrank (11) phenotypic match score. Phrank quantifies the overlap between any two sets of 
HPO phenotypic abnormalities and needs to be initialized with a set of known gene-phenotype 
associations. We initialized Phrank by using Ensembl ID-phenotype relationships derived from 
all Ensembl ID-article-phenotype relationships in the AMELIE knowledgebase if the Ensembl 
ID had a relevant gene score of at least 0.5 in the article and the article contained at most 100 
distinct HPO phenotypes. Given two sets of HPO phenotypic abnormalities P1 and P2, Phrank 
assigns a scalar phenotype match score to the two sets. We denote the Phrank score of two sets 
of phenotypes with match(P1, P2). We use the following abbreviations: “PV” = “patient variant”, 
“PTV” = “protein-truncating variant”, “NTV” = “non-truncating variant”, “EV” = “extracted 
variant” (variant mentioned in paper and extracted by AVADA). The 27 features of the AMELIE 
classifier are as follows: 
 Feature 1: M-CAP (29) (“MCAP score”): the average M-CAP score of all candidate 
causative variants in G. Since M-CAP provides scores only for rare missense variants, all 
variants for which no M-CAP score exist are assigned the M-CAP100 score described below. We 
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used M-CAP version 1.0, downloadable from 
http://bejerano.stanford.edu/mcap/downloads/dat/mcap_v1_0.txt.gz. 
 Feature 2: M-CAP100 (“100bp-average MCAP”): the arithmetic average of all available 
M-CAP scores in a window of -50, +50 basepairs adjacent to all candidate causative variants in 
G. If the M-CAP100 score does not exist, it is replaced by the M-CAPgene score described below. 
 Feature 3: M-CAPgene (“MCAP averaged over gene”): the arithmetic average of all 
available M-CAP scores for G. If the M-CAPgene score does not exist, it is replaced by the value 
0.0. 
 Feature 4: (“RVIS score”) the RVIS (31) score of G, or 100.0 if the RVIS score of G is 
not available. RVIS scores, version May 2015, were obtained from http://genic-
intolerance.org/data/RVIS_Unpublished_ExAC_May2015.txt .  
 Feature 5: (“pLI score”) the pLI (30) score of G, or 0.0 if the pLI score of G is not 
available. pLI scores version March 2016, for ExAC version 0.3, were obtained from 
ftp://ftp.broadinstitute.org/pub/ExAC_release/release0.3/functional_gene_constraint/forweb_clea
ned_exac_r03_march16_z_data_pLI.txt . 
 Feature 6: (“Patient PTV score”) the average protein-truncating score of all candidate 
causative variants in G. The protein-truncating score of a candidate causative variant is defined 
to be 1.0 if the variant is a splicing, stopgain, stoploss or frameshift variant, and 0.0 otherwise. 
 Feature 7: (“Average PV allele count”) the average ExAC (30) allele count of all 
variants in G. 
 Feature 8: (“Average PV allele count if PV het”) the ExAC allele count of the variant in 
G if it is a single heterozygous variant, and 0.0 otherwise. 
 Feature 9: (“PV is single heterozygous”) 1.0 if there is a single heterozygous variant in 
G, and 0.0 otherwise. 
 Feature 10: (“Number of EV in gene”) the number of variants in G that are mentioned in 
A. 
 Feature 11: (“Max relevant gene in paper”) the highest relevant gene score extracted 
from A. 
 Feature 12: (“#Genes with EV in paper”) the number of genes with at least one extracted 
genetic variant in A. 
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 Feature 13: (“Number of total EV in paper”) the total number of genetic variants 
extracted from A. 
 Feature 14: (“Paper PTV score”) the PTV score of A. 
 Feature 15: (“Paper NTV score”) the NTV score of A. 
 Feature 16: (“Paper dominant score”) the dominant score of A. 
 Feature 17: (“Paper recessive score”) the recessive score of A. 
 Feature 18: (“Full-text document relevance score”) the full document relevance score of 
A. 
 Feature 19: (“Phrank score (paper)”) the Phrank score of the patient’s phenotypes P with 
the phenotypes mentioned in the article (denoted by phenotypes(A)), divided by the maximum 




 Feature 20: (“Phrank score (patient)”) the Phrank score of the patient’s phenotypes P 
with the phenotypes mentioned in the article (denoted by phenotypes(A)), divided by the 




 Feature 21: (“PV equals EV”) the average same-type overlap score of each candidate 
causative variant in G. The same-type overlap score of a candidate causative variant is defined to 
be 1.0 if the patient’s variant overlaps an extracted variant in A of the same semantic effect, and 
0.0 otherwise. Two variants have the same semantic effect if they are both missense, 
nonframeshift indel, frameshift, stopgain or stoploss variants. 
 Feature 22: (“PV overlaps EV”) the average overlap score of each candidate causative 
variant in G. The overlap score of a candidate causative variant is defined to be 1.0 if the 
patient’s variant overlaps any extracted variant in A, and 0.0 otherwise. 
 Feature 23: (“Paper PTV score*Patient PTV score”) the PTV score of A (Feature 14) 




 Feature 24: (“Paper NTV score*Patient NTV score”) the NTV score of A (Feature 15) 
multiplied by the average non-truncating score of all candidate causative variant in G (defined as 
1-Feature 6). 
 Feature 25: (“Dominant score if PV het”) the dominant score of A (Feature 16) if there is 
a single heterozygous candidate causative variant in G, otherwise 0.0. 
 Feature 26: (“Recessive score if PV non-het”) the recessive score of A (Feature 17) if 
there is more than a single heterozygous candidate causative variant in G, otherwise 0.0. 
 Feature 27: (“Relevant gene score”) the relevant gene score of G in A. 
Most of these features were normalized by subtracting the mean feature value in the training set 
and dividing by the standard deviation of feature values in the training set, and subsequently 
clipped to be between -3.0 and +3.0. Features 9, 21, 22, which encode simple 0 or 1 flags 
indicating the presence or absence of a particular type of information were not normalized.  
Creating simulated patients 
To train AMELIE, we generated 681 simulated patients with Mendelian diseases. Each 
patient s was associated with  phenotypes Ps and a list of candidate causative variants (including 
a known causative variant). Further, each patient s was associated with a unique article As linking 
the causative variant to the patient’s phenotypes Ps. To generate simulated patients, we pursued 
the following high-level strategy (explained in detail below): first, we selected a set of OMIM 
diseases caused by a gene GC. Each combination of gene GC and disease D was associated with 
one article AC describing that mutations in GC cause D. Subsequently, we randomly selected a 
list of patient phenotypes P that are similar to phenotypes associated with D. Finally, we 
constructed a list of candidate causative variants by taking variants from a healthy individual and 
adding a single mutation in the gene GC that causes D. The simulated patient s was set to have 
disease Ds=D, causative gene GCs=GC, phenotypes Ps=P and an article As=AC describing that 
mutations in GCs cause Ds. 
Selecting a set of OMIM diseases D, each caused by one gene GC, along with an article 
describing that mutations GC cause D 
OMIM “Molecular Genetics” sections are sections in OMIM disease entries that textually 
describe molecular causes for a disease along with citations to original articles that first 
described the molecular causes for the disease. (E.g., the “Molecular Genetics section of the 
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OMIM entry on “Wilson Disease”: https://omim.org/entry/277900#molecularGenetics.) 
Molecular Genetics sections were downloaded from OMIM on February 15, 2017. To select a set 
of OMIM diseases, we first parsed the “Molecular Genetics” sections of the set of 4,948 OMIM 
diseases with a known molecular basis available up to July 2016 to find the first PubMed ID that 
did not occur in a subclause with the phrase “originally described” or “originally reported”. 
These “originally reported” subclauses usually refer to articles in which a cohort was originally 
described without identifying causative mutations. The first PubMed ID in the OMIM 
“Molecular Genetics” section that does not appear in a subclause with “originally described” or 
“originally reported” often links mutations in a gene to the disease. Thus, of those OMIM 
“Molecular Genetics” sections where we could parse a suitable PubMed ID, we took diseases 
where the first PubMed ID was published after 2011, resulting in a set of 1,363 OMIM diseases 
with causative genes and a PubMed ID that was published in 2011 or later.  
Selecting a random set of phenotypes for a simulated patient with an OMIM disease D 
Each of the OMIM diseases associated with an article was examined in order to create 
phenotypes for a simulated patient affected with the disease. To select a realistic set of simulated 
patient phenotypes for each disease, it is necessary to select some of the most important 
phenotypes of the disease with high probability while not selecting such a large set of 
phenotypes that diagnosing the patient using an automated method is trivial (e.g., by associating 
the patient with all phenotypes associated with the disease). OMIM “Clinical Features” sections 
give a textual description of clinical symptoms associated with a disease, often with the most 
striking and most-often occurring phenotypes mentioned first (e.g., the clinical features of 
Wilson Disease: https://omim.org/entry/277900#clinicalFeatures). OMIM “Clinical Features” 
sections were downloaded on February 15, 2017. To determine which the most striking and 
most-often occurring phenotypes were for a particular disease D, we first parsed the “Clinical 
Features” section of the corresponding OMIM entry for disease D using the AMELIE phenotype 
recognizer. The phenotypes recognized in the “Clinical Features” section were output in the 
order of first recognition. If no phenotypes were parsed from the “Clinical Features” section, the 
disease D was not used to construct a simulated patient. OMIM “Clinical Synopsis” sections list 
clinical features using HPO terms (e.g., the clinical synopsis of Wilson Disease: 
https://omim.org/clinicalSynopsis/277900). OMIM “Clinical Synopsis” sections were 
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downloaded on February 17, 2017. We saved a separate set of HPO phenotypes associated with 
the disease D by OMIM in the “Clinical Synopsis” section that were not already recognized in 
the “Clinical Features” section. Intuitively, the features described in the free-text “Clinical 
Features” sections are often the most important phenotypes associated with the disease, while 
many of the phenotypes mentioned in the “Clinical Synopsis” section are less important and 
occur less frequently. Subsequently, we refer to the phenotypes parsed from the “Clinical 
Features” section as “key phenotypes”, and phenotypes listed in “Clinical Synopsis” as “other 
phenotypes”. To construct a random set of HPO phenotypes for a patient with a given OMIM 
disease D, we selected a subset of the set of key phenotypes parsed from the “Clinical Features” 
section and the other phenotypes from the “Clinical Synopsis” section of the OMIM entry for D 
using the following strategy: the first mentioned key phenotype in the “Clinical Features” section 
received a weight of 1.0. Subsequently mentioned key phenotypes received a weight of 0.6 times 
the weight of the previous key phenotype. The other phenotypes all received a weight of 0.25 
times the lowest weighted key phenotype. The weights were converted to a phenotype 
probability mass function (hence called PMFP) by dividing each weight by the sum of all 
weights assigned to phenotypes of the disease. Let IPMFP be defined as the probability mass 
function that is achieved by taking the reciprocal value of each entry in PMFP and dividing by 
the total sum of weights in IPMFP. Subsequently, a target fraction match score t was picked from 
a normal distribution with mean 20% and standard deviation 10%. If the target fraction match 
score was less than 5%, it was set to 5%. The goal of the random phenotype generator was now 
to select a set of simulated phenotypes F from the above probability mass function over HPO 
phenotypes for the given disease D such that the fraction match score over the set of all key and 




was as close to the target fraction match score as possible. 100 random draws of phenotypes 
were generated in the following manner: the number of phenotypes n to draw was determined by 
rounding a draw from a Gaussian distribution with mean 7 and standard deviation 4 to the 




 was smaller than the target fraction match score, previously unselected 
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phenotypes were uniformly drawn and added to F until 
𝑚𝑎𝑡𝑐ℎ(𝐹,𝑂)
𝑚𝑎𝑡𝑐ℎ(𝑂,𝑂)
 was greater than the target 
fraction match score. Subsequently, while 
𝑚𝑎𝑡𝑐ℎ(𝐹,𝑂)
𝑚𝑎𝑡𝑐ℎ(𝑂,𝑂)
 was greater than the target fraction match 
score, a phenotype was selected using the probability mass function IPMFP and replaced by one 
of its parents in the HPO DAG until 
𝑚𝑎𝑡𝑐ℎ(𝐹,𝑂)
𝑚𝑎𝑡𝑐ℎ(𝑂,𝑂)
 was less than the target fraction match score. Of 
the 100 sets of simulated phenotypes for disease D, the set F was selected which minimizes the 
function 
𝐽(𝐹) = |𝑡 −  
𝑚𝑎𝑡𝑐ℎ(𝐹, 𝑂)
𝑚𝑎𝑡𝑐ℎ(𝑂, 𝑂)
| + 0.001 ∗ min(3, #𝑎𝑏𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑡𝑖𝑒𝑠(𝐹)), 
where #abnormalities(F) is defined as the number of HPO phenotypes whose name starts with 
“abnormality of …” or “abnormal …”. These phenotypes are far less likely to be selected by a 
human phenotype annotator than by an automated algorithm, and were therefore penalized by the 
automatic phenotype selection algorithm. If the set F out of the 100 picked sets with the lowest 
J(F) has J(F) > 0.05, the disease D was not used to construct a simulated patient. 
Creating a set of candidate causative variants for a simulated patient with an OMIM disease D 
To construct a genotype of a simulated patient that is causative of disease D, all candidate 
causative variants from a random 1000 genomes project participant were taken. Subsequently, a 
pathogenic (CLNSIG=5) ClinVar variant (from ClinVar file date 20160705, downloaded from 
ftp://ftp.ncbi.nlm.nih.gov/pub/clinvar/vcf_GRCh37/archive_1.0/2016/clinvar_20160705.vcf.gz) 
in the causative gene GC that was associated with disease D was randomly selected and added to 
the patient’s genotype. If no such variant existed, the disease D was not used to construct a 
simulated patient. The zygosity of the variant was determined as follows: first, the inheritance 
mode of the disease D was parsed from the OMIM field “phenotypeInheritance” in the 
“geneMap” section. These data sections were downloaded from OMIM on May 17, 2017. If the 
disease was annotated as dominant, the variant was set to be heterozygous; if the disease was 
recessive, the variant was set to be homozygous. Diseases without a unique OMIM-assigned 
inheritance mode were skipped. If the inheritance mode could not be parsed from OMIM, the 
disease D was not used to construct a simulated patient.  
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Creating a training set for the AMELIE classifier using simulated patients 
The simulated patients, each associated with a disease Ds, a causative gene GCs, an article As 
describing that mutations in GCs cause Ds, a list of phenotypes and a list of candidate causative 
variants, were used to construct a training set for the AMELIE classifier. The training set 
consists of a set of triples (P, G, A), where P is a list of phenotypes, G is a candidate causative 
gene (i.e., a gene containing at least one of the patient’s candidate causative variants), and A is an 
article about G. Each of these triples either receives a label “true” or “false” (to be used in the 
training set), or are unlabeled (and discarded from the training set):  
 The triple (Ps, GCs, As) containing both the causative gene GCs and the article As 
describing that mutations in GCs cause Ds was supervised true. 
 All other triples including a patient’s causative gene GCs were discarded from the 
training set (i.e., neither supervised true nor false). 
 All triples (Ps, G, A) containing a gene G not equal to the simulated patient s’s causative 
gene GCs were supervised “false”. 
Due to the abundance of negative training examples, the total set of negatives was randomly 
subsampled to 1000x the size of the positive training set. Supervised triples (P, G, A) were 
converted into feature vectors of 27 features described above. A scikit-learn (41) 0.20.0 
LogisticRegression classifier with options class weight=“balanced” and default parameters 
otherwise was trained on the data created from the simulated patients to act as the AMELIE 
classifier. GNU parallel (44) was used to speed up parts of the computation. 
Ranking candidate causative genes using the AMELIE classifier 
AMELIE assigns each candidate gene G the score of its highest-scoring triple (P, G, A) using 
the following formula: 
𝑠𝑐𝑜𝑟𝑒(𝐺) = 𝑚𝑎𝑥𝐴∈{𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑎𝑏𝑜𝑢𝑡 𝐺}  AMELIE_classifier(𝑃, 𝐺, 𝐴) 
Evaluating AMELIE on a patient set from DDD 
VCF files of patients submitted to the Deciphering Developmental Disorders (33) (DDD) 
project were downloaded from the European Genome-Phenome Archive (40) (EGA) study 
EGAS00001000775. Variant filtering to candidate causative variants was performed as described 
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above in Methods section “Variant filtering to arrive at candidate causative variants and genes”. 
All patients with a single-gene diagnosis, with the causative variant present in their associated 
Variant Call Format (VCF) file and in the candidate causative gene list, that was not due to a 
structural variant and for which the causative gene was not a novel discovery of the DDD project 
were selected. From any diagnosed set of siblings, a single diagnosed sibling was selected at 
random, resulting in a final patient test set of 215 patients. 
Ranking candidate causative genes using the AMELIE classifier 
The final AMELIE score of a triple (P, G, A) is defined to be the output of the AMELIE 
classifier on (P, G, A) if the classifier output is less than 0.95. Otherwise, it is defined to be  (0.95 
+ 0.05 * match(patient_phenotypes, article_phenotypes) / match(patient_phenotypes, 
patient_phenotypes)). This is because for genes with a very high AMELIE classifier score (>= 
0.95), the raw phenotype match score (calculated as match(patient_phenotypes, 
article_phenotypes) / match(patient_phenotypes, patient_phenotypes)) is more indicative of a 
good match of article to patient than the raw output of the AMELIE classifier. Each candidate 
causative gene is assigned the AMELIE score of its highest-ranking article. 
Comparisons of AMELIE to other methods 
All comparisons of AMELIE gene ranking results to other automatic gene ranking 
algorithms’ ranking results were performed by running the automatic gene ranking algorithms 
described below, and subsetting the output list of ranked genes to the same list of candidate 
genes that were also used by AMELIE (Figure 2a). This ensures a fair comparison between 
AMELIE and all other automatic gene ranking methods, because all methods are ultimately 
measured for their ability to rank the same set of candidate genes. In case an automatic gene 
ranking method did not output the causative gene in its output list of ranked genes for a patient, 
the causative gene was given a rank equal to the number of ranked genes plus half the number of 
all unranked candidate causative genes (11). Since causative genes for DDD, Stanford, and 
Manton patients are given as HGNC gene symbols, and all compared tools (including AMELIE) 
output ranked lists of HGNC gene symbols, we computed causative gene ranks using ranked lists 
of HGNC gene symbols. Tied scores in the output of any methods were broken by 
alphanumerically sorting HGNC gene symbols. 
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One-sided Wilcoxon signed-rank tests were performed using the R function  
wilcox.test(ranks1, ranks2, paired=TRUE, alternative=”less”)  
When training each of the classifiers that build the AMELIE knowledgebase, we made sure 
not to train on any article about the causative genes in any of the 215 DDD patients. Nor was any 
simulated patient assigned a causative gene from the list of DDD patients’ causative genes. 
Comparison to Exomiser 
The output of Exomiser (14) version 11.0.0 was obtained by running the Exomiser Command 
Line Interface (exomiser-cli) version 11.0.0, obtained from 
https://github.com/exomiser/Exomiser/releases/download/11.0.0/exomiser-cli-11.0.0-
distribution.zip, on all patients. The following command line was used: 
java -Xms2g -Xmx4g -jar /cluster/u/jbirgmei/Downloads/exomiser/exomiser-cli-
11.0.0/exomiser-cli-11.0.0.jar --analysis patient.yml 
The file patient.yml contained a link to the patient’s VCF file and the patient’s candidate gene 
list and was based on the file test-analysis-exome.yml in the Exomiser V11 distribution zip file. 
For each patient, each gene was associated with the “combinedScore” output for the gene by 
Exomiser. The Exomiser output contained the causative gene in 271 (100%) real patient test 
cases and 676 (99%) simulated patient cases. Genes were sorted by the Exomiser combinedScore 
(high-to-low) and subset to the subset to the list of candidate genes used by AMELIE in order 
to arrive at causative gene ranks. 
Comparison to Phenolyzer 
The output of Phenolyzer (15) was obtained by running the Phenolyzer executable from 
https://github.com/WGLab/phenolyzer, commit number 
80596ac3affc565e178dcff3a308e408be0ab94f from September 11, 2018, using the command 
line 
perl phenolyzer/disease_annotation.pl "<patient HPO IDs semicolon-separated>" -p -ph -





The Phenolyzer output contained the causative gene in 265 (98%) real patient cases and 655 
(96%) simulated patient cases. Genes in the output of Phenolyzer were subset to the same 
candidate gene list used by AMELIE and all other methods and sorted by associated score 
(high-to-low) to arrive at causative gene rankings. 
Comparison to eXtasy 
The output of eXtasy (17) was obtained by running the eXtasy Command Line Interface 
cloned from GitHub (commit number 6fe9d418f05d198e0504f3d0327a4f4ebb7e3fbd from 
February 19, 2014) on all patients.  
./extasy.rb -i <patient_vcf_filename> -g <encoded patient HPO IDs> -c 
The eXtasy output contained the causative gene in 188 (69%) real patient cases and 368 
(54%) simulated patient cases. A sample of cases where eXtasy would not rank the true causal 
gene were spot checked manually, to no better results. The output genes were subset using the 
same list of candidate causative genes that was used to evaluated AMELIE and all other 
methods and sorted by the eXtasy “extasy_combined_order_statistics” score (low-to-high) to 
arrive at causative gene ranks. 
Comparison to Phen-Gen 
The output of Phen-Gen (16) was obtained by running the Phen-Gen V1 executable 
downloaded from http://54.173.20.191/downloadexe.php?file=Phen-GenV1.tar.gz using the 
command line 
perl phen-gen.pl input_phenotype=<patient phenotypes file, containing patient HPO IDs 
newline-separated> input_vcf=<patient VCF file> input_ped=<patient pedigree file> 
The Phen-Gen output contained the causative gene in 67 (25%) real patient cases and 363 
(53%) simulated patient cases. A sample of cases where Phen-Gen would not rank the true causal 
gene were spot checked manually, to no better results. Genes associated with scores output by 
Phen-Gen (“PROBABILITY_DAMAGING” column) were subset to the same list of candidate 
causative genes used by AMELIE and all other compared methods here and sorted by 
associated score (high-to-low) to arrive at causative gene ranks. 
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Comparison to PubCaseFinder 
The output of PubCaseFinder (18) was obtained by querying the PubCaseFinder API 
(https://pubcasefinder.dbcls.jp/mme/match) on November 14, 2018 by querying the URL 
https://pubcasefinder.dbcls.jp/mme/match with content type 
application/vnd.ga4gh.matchmaker.v1.0+json based on the instructions given in 
https://github.com/ga4gh/mme-apis/blob/master/search-api.md. A list of HPO IDs and the list of 
candidate genes was provided to PubCaseFinder for each patient. Each gene in the output was 
associated with its maximum associated score in the output of PubCaseFinder. The 
PubCaseFinder API output contained the causative gene for 189 (70%) real test patients and 392 
(58%) simulated patients. PubCaseFinder output genes were subset to the same list of 
candidate causative genes used by AMELIE and all other methods compared here to arrive 
at the causative gene rank. 
Determining the number of genes to examine for 90% diagnosis rate across all gene ranking 
methods 
For each automatic gene ranking method, we determined the minimum number n such that the 
top-ranked n genes would include the causative gene in at least 90% of the test patients. 
Calculating the speedup achieved by each gene ranking method over a random baseline 
For each automatic gene ranking method, the ranks of the causative genes were summed to 
arrive at the number of genes to investigate until arriving at the causative gene for all patients, 
assuming a clinician went through the prioritized gene lists in the returned order. The random 
baseline was estimated by assuming arrival at the causal gene after inspecting half the candidate 
gene list of every patient. The speedup was calculated by dividing the total size of the set of 
genes in the random baseline (summed across all patients) by the summed ranks of the causative 
genes. 
Collection of patient data for Stanford and Manton Center cases 
VCF files for 21 Manton patients were obtained from the Manton Center Gene Discovery 
Core. ClinPhen, a tool that automatically extracts phenotypes from medical records, was used to 
extract 3 top-prioritized HPO phenotypes each from anonymized patient medical records 
obtained from the Manton Center, as in (19). Raw sequencing data in FASTQ format for 35 
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Stanford patients were obtained from the Medical Genetics Service at Stanford Children’s 
Health. FASTQ files of Stanford patients were aligned to the GRCh37/hg19 human genome 
assembly using bwa-mem version 0.7.0-r789, with default parameters (45), and variants were 
called using Genome Analysis Toolkit (GATK) version 3.4-46-gbc02625 following the 
HaplotypeCaller workflow in the GATK best practices (46) as previously described (21). HPO 
phenotypes associated with these patients were manually created from the medical record and 
subsequently reviewed by a clinician. Variant filtering for rare, functional variants was 
performed in the same manner as for the DDD patients. For both subsets, all cases with available 
phenotypic and genotypic data for which the causative gene was in the candidate genes list were 
selected. Ranking of candidate causative genes after processing by the AMELIE classifier, 
calculating the speedup over a random baseline, determining the number of genes to investigate 
for a 90% diagnosis rate, and comparison against other gene ranking methods was performed as 
described for the DDD patients.  
Cross-validation of AMELIE classifier on simulated patients 
To test gene ranking performance on simulated patients, we split the set of simulated patients 
into 5 evenly sized chunks. In five round-robin iterations, we re-trained the AMELIE classifier 
using 4 of the 5 chunks of simulated patients, and evaluated the re-trained classifier’s causative 
gene ranking performance on the remaining fifth chunk of simulated patients (5-fold cross-
validation).  
Genotypes and phenotypes for simulated patients were obtained as described for the training 
set of the AMELIE classifier. Calculating the speedup compared to a random baseline, causative 
gene rank cutoff for a 90% diagnosis rate, and comparison against other methods were 
performed as above for the DDD patients. 
AMELIE ranked the causative gene at the top in 621 cases (91%) and in the top 10 in 672 
cases (99%), replicating previous results indicating far higher gene ranking performance on 
simulated patient data compared to real-world data (12, 13, 15, 16, 47, 48). Compared to a 
random baseline, AMELIE speeds up causative gene discovery by 34.8x on simulated patients. 
The next best method, Exomiser, speeds up causative gene discovery by 17.9x and other 
methods perform worse (figure S4, table S7).  
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Determining contribution of AMELIE classifier features to performance 
Determining the most, 2nd-most, and 3rd-most highly weighted features of the AMELIE classifier 
across all real patients 
To determine the top most influential features for each patient, we analyzed all patients with 
causative gene rank 1. Because the AMELIE classifier is implemented as a logistic regression 
classifier, each feature is associated with a global weight. The numerical feature value of each 
feature associated with the top-ranked article about the causative gene was multiplied by the 
AMELIE classifier weight of the feature, yielding the 3 highest weighted features for each 
patient with causative gene rank 1. 
Feature ablation analysis 
6 AMELIE classifiers with reduced feature sets were re-trained on the same training set used 
to train the fully featured AMELIE classifier. The features removed from each of the 6 feature-
ablated classifiers are listed in table S13. 
Augmenting phenotype recognition in articles does not lead to increased performance 
HPO cross-links some of its phenotype entries to other databases containing phenotype 
names. We utilized 19,949 cross-links available in HPO by augmenting HPO phenotype phrases 
with synonyms from UMLS (35), MeSH (36), and SNOMED-CT (37), three databases 
containing phenotype names. This augmentation of recognizable phenotype names increased the 
number of distinct recognized phenotypic abnormalities per article in the AMELIE 
knowledgebase from 9 to 22. However, on the main task of causative gene ranking, the 
augmented AMELIE knowledgebase did not perform better (169 instead of 175 patients had the 
causative gene ranked at the top). 
Medical Subject Headings (MeSH) (36) data was downloaded from 
ftp://nlmpubs.nlm.nih.gov/online/mesh/MESH_FILES/asciimesh/c2018.bin and 
ftp://nlmpubs.nlm.nih.gov/online/mesh/MESH_FILES/asciimesh/d2018.bin on October 15, 
2018. SNOMED-CT (37) data was downloaded from 
https://download.nlm.nih.gov/mlb/utsauth/USExt/SnomedCT_USEditionRF2_PRODUCTION_2
0180901T120000Z.zip on October 15, 2018. Unified Medical Language System (UMLS) (35) 
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data was downloaded from 
https://www.nlm.nih.gov/research/umls/licensedcontent/umlsknowledgesources.html on October 
15, 2018. Cross-links (XREF) in HPO phenotype entries were used to associated HPO phenotype 
IDs with IDs of phenotypes in MeSH, SNOMED-CT, and UMLS. UMLS IDs and phenotype 
phrases were obtained from files MRCONSO.RRF.a*.gz (columns 1 and 15). SNOMED IDs and 
phenotype phrases were obtained from file Full/Terminology/sct2_Description_Full-
en_US1000124_20180901.txt (columns 5 and 8). MeSH IDs and phenotype phrases were parsed 
from files c2018.bin and d2018.bin, fields “UI” (ID), “NM” (name) and “SY” (synonyms). All 
UMLS, MeSH and SNOMED CT phenotype phrases were processed in the same fashion HPO 
phenotype names and synonyms were processed. After augmenting HPO synonyms with 
synonyms stored in UMLS, MeSH and SNOMED CT, AMELIE could recognize the 13,439 
HPO phenotypic abnormalities using 343,705 phenotype names and synonyms. AMELIE 
phenotype recognition was subsequently run on all downloaded full-text articles, and the 
AMELIE knowledgebase augmented with newly identified phenotype mentions. The AMELIE 
classifier was then re-trained on the augmented database, and the augmented database and 
modified classifier were used to rank candidate causative genes for all real test patients. 
AMELIE knowledgebase constructed from full text is up to 43% superior to title/abstract-only  
knowledgebase on clinical patients 
To quantify the information gained from full text for the purpose of causative gene ranking 
compared to title/abstract-only data, we re-trained all AMELIE knowledgebase classifiers only 
on title/abstract data from PubMed. Subsequently, we constructed the AMELIE knowledgebase 
using title/abstract data from PubMed only and re-trained the AMELIE classifier using the 
title/abstract-only knowledgebase.  
To construct the AMELIE knowledgebase using only title/abstract data from PubMed, we fed 
the title and abstract of each article in place of the full text to all components involved in 
constructing the AMELIE knowledgebase. Classifiers involved in construction of the AMELIE 
knowledgebase (relevance classifiers, relevant gene classifier, dominant/recessive classifier, 
variant type classifier) were re-trained on this data. PubMunch download of full-text articles was 
disabled. AVADA full text variant data was omitted. The AMELIE classifier was re-trained on 
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the title/abstract-only knowledgebase using data derived from the 681 simulated patients 
described above. 
Title/abstract-based gene ranking performs significantly worse than ranking based on full text 
information across all 271 real test patients (p=1.87*10-3; one-sided Wilcoxon signed rank test). 
On the set of clinical patients from Stanford and Manton, 43% more patients had their causative 
genes ranked at the top using full-text based ranking compared to title/abstract-based ranking. 
Overall, title/abstract-based ranking put the causative genes of 133 of 271 real patients at the top, 
compared with 175 (+32%) of 271 real patients for full-text based AMELIE. 
Comparing causative gene rank vs. number of articles analyzed by AMELIE 
Linear regression and the Wald test for the slope of linear regression between AMELIE 
causative gene ranks and number of articles analyzed by AMELIE for the causative gene for 
each patient were performed using the Python 3.7.0 package scipy version 1.1.0 using the 
method scipy.stats.linregress, which returns the Wald test p-value.  
Comparisons of AMELIE knowledgebase to DisGeNET and AMELIE classifier to Phrank 
Constructing a DisGeNET version of the AMELIE knowledgebase 
Multiple previous methods for text mining gene, disease, variant, and phenotype information 
from literature have been developed (49–58), most of which curate limited information or 
information from comparatively small sets of articles. Of 3 additional efforts (38, 59, 60) 
attempting to curate gene-phenotype information from a broad set of articles in automatic or 
semi-automatic fashion, we focused on DisGeNET (the most recently updated such database), 
containing gene-phenotype relationships, disease-causing variants, and links to primary literature 
from PubMed. DisGeNET contains both automatically curated data and hand-curated data (38).  
DisGeNET data were downloaded from http://www.disgenet.org/ds/DisGeNET/results/ on 
October 5, 2018. Files containing all gene-disease-PubMed ID associations, all variant-disease-
PubMed ID associations, BeFree gene-disease-PubMed ID associations, BeFree variant-disease-
PubMed ID associations, mappings from DisGeNET gene identifiers to Ensembl gene 
identifiers, and mappings from DisGeNET disease identifiers to HPO IDs were downloaded. For 
BeFree, manually curated data, and both data sources in DisGeNET, we used the following 
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procedure to fill the AMELIE knowledgebase: we converted all DisGeNET disease identifiers to 
HPO version releases/2018-07-25 IDs where possible according to DisGeNET-provided 
mappings, all DisGeNET gene identifiers to Ensembl version 84 gene identifiers where possible 
according to DisGeNET-provided mappings, and then added all articles associated with at least 
one Ensembl ID and one mentioned HPO ID to the DisGeNET version of the AMELIE 
knowledgebase. Subsequently, we converted all variants (in form of dbSNP rsIDs) to genomic 
coordinates, and added those variants that were associated with an article to the variants table in 
the DisGeNET version of the AMELIE knowledgebase.  
Three different versions of DisGeNET information were used: (1) containing only data 
curated by DisGeNET’s BeFree automatic curation software, (2) containing only manually 
curated data in DisGeNET, (3) containing all suitable data in DisGeNET, both manually and 
automatically curated. Subsetting DisGeNET to only data curated by DisGeNET’s BeFree 
automatic curation software resulted in a total of 256,902 articles associated with a median of 1 
Ensembl gene per article, and a median of 1 genetic variant in 16,292 articles. Subsetting 
DisGeNET to only manually curated data resulted in a total of 59,472 articles, associated with a 
median of 1 Ensembl gene per article, and no genetic variants associated with articles. Taking all 
suitable data in DisGeNET resulted in 287,428 articles. 
3 AMELIE classifiers were subsequently trained on data derived from the 681 simulated 
patients using data in the 3 versions of the DisGeNET knowledgebase analogous to the strategy 
described above for the full-text AMELIE knowledgebase. Causative gene ranks for the 271 real 
test patients were obtained using the 3 versions of the DisGeNET knowledgebase analogous to 
how they were obtained using data in the AMELIE knowledgebase. All 3 versions of DisGeNET 
performed worse than AMELIE (all p-values ≤ 4.76*10-23, one-sided Wilcoxon signed rank test). 
Best-performing was the DisGeNET database with automatically curated data (68 causative 
genes ranked at the top, compared to 175 for original AMELIE; table S10). 
Using Phrank to rank genes using information in the AMELIE knowledgebase 
We replaced the AMELIE classifier by the Phrank (11) phenotypic match score to rank 
patient candidate genes. The Phrank phenotypic match score (11) was initialized with a database 
of gene-phenotype associations derived from the AMELIE knowledgebase as above for the 
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Phrank phenotypic match score features in the AMELIE classifier. Given a patient associated 
with a list of HPO phenotypes and a list of candidate causative genes, we calculated the Phrank 
phenotypic match score between the patient and each article about one of the patient’s candidate 
causative genes. Each candidate gene was then associated with: (1) the highest Phrank 
phenotypic match score of any article about the candidate gene, and (2) the AMELIE full-text 
document relevance score of the highest-ranked article about the candidate gene. The candidate 
genes were sorted (high-to-low) first by their associated phenotypic match score, and (to break 
ties), by their associated full-text relevance score (also high-to-low). This procedure was 







Figure S1. Number of phenotypes associated with genes through articles in the AMELIE 
knowledgebase. Genes are ordered by number of associated phenotypes (descending left-to-





Figure S2. The accelerated accumulation of curated facts in Mendelian genomics. The 







Figure S3. Replication of AMELIE’s causative gene ranking performance on 56 clinical 
patients from Stanford and Manton. We evaluated AMELIE against the other gene ranking 
tools on a set of 56 patients from Stanford Children’s Health and the Manton Center for Orphan 
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Disease Research. (a) Number of genes ranked at the top, ranked 1-2, and ranked 1-3, by 
different candidate causative gene ranking methods. (b) Number of top-ranked genes to 
investigate for a 90% diagnosis rate by different methods. (c) Speedup of diagnosis when 




Figure S4. Cross-validation of AMELIE’s causative gene ranking performance on 681 
simulated patients. We evaluated the AMELIE causative gene ranking performance on 681 
simulated patients using 5-fold cross-validation (where 80% of the simulated patients were used 
for training and 20% were evaluated, in 5 rounds). As in Figure S3, the panels show (a) raw 
causative gene ranking performance, (b) number of genes to investigate for a 90% diagnosis rate, 




Figure S5. Essence of the interface at https://AMELIE.stanford.edu. Inputs: (A) Clinicians 
upload a VCF file (variant list) of an affected patient. Using a number of adjustable parameters, 
variant frequency thresholds are set to define a subset of candidate causative variant. Optionally, 
one can upload just a list of candidate genes. (B) Clinicians describe the patient using Human 
Phenotype Ontology terms. Outputs: (C) AMELIE outputs a list of ranked candidate genes along 
with literature that support this gene as being causative of the patient’s disease. (D) Upon 
selecting an article from Panel C, AMELIE displays a comparison of patient phenotypes with 






(See attached Excel file for table contents.) 
Table S1. Full-text gene extraction statistics. Mean, median, standard deviation, and 
interquartile range of number of candidate genes (including many false positives) discovered in 
all downloaded full text articles, vs. the number of genes with relevance score >= 0.1 per article 
that ultimately made their way to the AMELIE knowledgebase. 
Table S2. Extraction statistics from the 100 most-used journals. Number of gene-phenotype 
relationships and number of downloaded articles from top 100 journals with most extracted 
gene-phenotype relationships. 
Table S3. Simulated patient details. Containing ID of 1000 genomes person used as basis for 
genotype, causative gene, assigned OMIM disease, list of synthetically generated phenotypic 
abnormalities for the disease (canonicalized up to “phenotypic abnormality”, i.e., adding all 
ancestors of the assigned phenotype in the HPO directed acyclic graph of phenotypes up to the 
node “phenotypic abnormality”), number of phenotypic abnormalities assigned to the patient 
(canonicalized), number of phenotypic abnormalities associated with the OMIM disease 
provided by HPO build 149 (downloaded on September 27th, 2018, from 
http://compbio.charite.de/jenkins/job/hpo.annotations.monthly/149/artifact/annotation/ALL_SO
URCES_ALL_FREQUENCIES_diseases_to_genes_to_phenotypes.txt) (canonicalized),  
fraction of overlapping patient and HPO phenotypes over HPO phenotypes. 
Table S4. DDD patient details. DDD patients, with number of candidate causative genes, 
causative gene, causative gene ranks across all compared gene ranking methods, and list of 
patient phenotypes. 
Table S5. Searching for top-ranked AMELIE articles in OMIM. Top-ranked articles about 
the causative gene by AMELIE, indicating whether the article is cited in OMIM or not. 
Table S6. Stanford and Manton clinical patient details. Stanford and Manton patients with 




Table S7. Simulated patient gene ranking results. Simulated patients, number of candidate 
causative genes, assigned causative gene, and gene ranks across all compared gene ranking 
methods. 
Table S8. Most important features for patients with top-ranked causative genes. Real 
patients where AMELIE ranked the causative gene at the top, along with the top 3 highest most 
contributing features to the top-ranked article about the causative gene. 
Table S9. AMELIE classifier feature ablation results. Real patients with AMELIE causative 
gene ranks after removing features from the AMELIE classifier. 
Table S10. DisGeNET gene ranking results. AMELIE gene ranks of real patients when using 
the DisGeNET knowledgebase instead of the AMELIE knowledgebase.  
Table S11. Regular expression patterns used to parse variant type from OMIM Allelic 
Variant entries. 
Table S12. Phenotypes extracted from full-text articles by AMELIE, indicating whether the 
phenotype was extracted correctly or not. Phenotypes are counted as correctly extracted if 
they are mentioned as applying to humans, not as parts of word groups. E.g., the words “liver 
failure” are correctly extracted to HP:0001399 (Hepatic failure) in PubMed ID 15703195, but the 
word “shock” is incorrectly extracted to HP:0031273 (Shock) in PubMed ID 2702668 because it 
only occurs as part of “heat shock protein” in the article. 
Table S13. Assignment of features to feature groups. 
